البلد: أيرلندا
اللغة: الإنجليزية
المصدر: HPRA (Health Products Regulatory Authority)
Caspofungin
Ethypharm
J02AX; J02AX04
Caspofungin
50.00 milligram(s)
Powder for concentrate for solution for infusion
Other antimycotics for systemic use; caspofungin
Not marketed
2017-05-12
HealthProductsRegulatoryAuthority 12June2019 CRN008YFF Page1of14 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Caspofungin50mgpowderforconcentrateforsolutionforinfusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Caspofungin50mgpowderforconcentrateforsolutionforinfusion Eachvialcontains50mgcaspofungin(asacetate). Afterreconstitutionin10.5mlofwaterforinjection,1mlof concentratecontains5.2mgofCaspofungin. Forthefulllistofexcipients,seesection6.1. 3 PHARMACEUTICAL FORM Powderforconcentrateforsolutionforinfusion. Beforereconstitution,thepowderisawhitetooff-white-compact,powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS -Treatmentofinvasivecandidiasisinadultorpaediatricpatients. - Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericinB,lipidformulationsofamphotericinBand/oritraconazole.Refractorinessisdefinedasprogression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. -Empiricaltherapyforpresumedfungalinfections(suchasCandidaorAspergillus)infebrile,neutropaenicadultor paediatricpatients. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Caspofunginshouldbeinitiatedbyaphysicianexperiencedinthemanagementofinvasivefungalinfections. Posology _Adult patients_ Asingle70mgloadingdoseshouldbeadministeredonDay-1,followedby50mgdailythereafter.Inpatientsweighingmore than 80 kg, after th اقرأ الوثيقة كاملة